Výsledky vyhledávání

Direct inhibition of protein Ca by site directed thrombin inhibitors: Implications in anticoagulant and thrombolytic therapy

Autor: Demetra D. Callas, Jawed Fareed

Publikováno v: Thrombosis Research. 78:457-460

Several synthetic and recombinant antithrombin agents are currently developed for anticoagulation during thrombolytic therapy. Many of these agents are designed to inhibit thrombin at the active site. This active site is similar in enzymes belonging

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ddf64f5520b98a34bd6b7953f0deab
https://doi.org/10.1016/0049-3848(95)99612-c

Zobrazit plný text záznamu

Section Review—Cardiovascular & Renal: Recent Developments in Antithrombotic Agents

Autor: Jawed Fareed, Walter Jeske, Debra Hoppensteadt, Jeanine M. Walenga, Demetra D. Callas

Publikováno v: Expert Opinion on Investigational Drugs. 4:389-412

During the past decade, many significant developments in the clinical management of thrombotic and vascular disorders have occurred. In particular, several newer approaches for the prophylactic and therapeutic management of such disorders as venous t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b8b99bdf8e94504d39580fa7ae86af48
https://doi.org/10.1517/13543784.4.5.389

Zobrazit plný text záznamu

Studies on the Thrombogenic Effects of Recombinant Tissue Factor

Autor: Peter Bacher, Jawed Fareed, Demetra D. Callas

Publikováno v: Seminars in Thrombosis and Hemostasis. 21:166-176

An exposure of blood to tissue factor (TF) activates the coagulation system by the extrinsic pathway and may cause clot formation. Recombinant TF (r-TF) has been produced and subsequently reconstituted into phospholipid vesicles. The aim of these stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d585c16f7a6d044b7f37598434c25a26
https://doi.org/10.1055/s-2007-1000392

Zobrazit plný text záznamu

Comparative Studies on the Anticoagulant and Protease Generation Inhibitory Actions of Newly Developed Site-Directed Thrombin Inhibitory Drugs

Autor: Debra Hoppensteadt, Demetra D. Callas, Jawed Fareed

Publikováno v: Seminars in Thrombosis and Hemostasis. 21:177-183

Site-directed thrombin inhibitors are being currently assessed clinically for their antithrombotic efficacy. Although these agents are claimed to be specific and direct thrombin inhibitors, their mechanism of inhibition varies. The objective of these

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5dd4f2b21c6bde156a66c38029c96309
https://doi.org/10.1055/s-2007-1000393

Zobrazit plný text záznamu

Fibrinolytic Compromise by Synthetic and Recombinant Thrombin Inhibitors: Implications in the Treatment of Thrombotic Disorders

Autor: Debra Hoppensteadt, Jawed Fareed, Omer Iqbal, Demetra D. Callas

Publikováno v: Clinical and Applied Thrombosis/Hemostasis. 1:114-124

Site-directed synthetic and recombinant antithrombin agents are widely used to prevent reocclusion during thrombolytic therapy in acute myocardial infarction and other vascular occlusive disorders. However, minimal studies have been conducted to exam

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1cf076c9cf0a72157d00b3d414234e09
https://doi.org/10.1177/107602969500100203

Zobrazit plný text záznamu

Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin

Autor: Omer Iqbal, Jawed Fareed, Peter Bacher, Demetra D. Callas, Debra Hoppensteadt

Publikováno v: Thrombosis Research. 74:193-205

Newly developed synthetic and recombinant thrombin inhibitors possess strong anticoagulant effects. Despite these effects, interactions of these agents with enzymes in the fibrinolytic network result in the modulation of such proteases as t-PA, u-PA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2181eb7b6e9de341ab810bc7867e42d8
https://doi.org/10.1016/0049-3848(94)90108-2

Zobrazit plný text záznamu

Molecular weight and biochemical profile of a chemically modified heparin derivative, Suleparoide®

Autor: Demetra D. Callas, Omer Iqbal, Ahmad Ahsan, Jawed Fareed

Publikováno v: Thrombosis Research. 69:369-376

Recently, a new chemically modified derivative of heparin (Suleparoide®, Syntex Laboratories Buenos Aires, Argentina) was introduced for the prophylaxis of thrombosis and treatment of vascular disorders. This agent is claimed to contain a depolymeri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dbdcd8fde3f68bd89af87e744edfa55
https://doi.org/10.1016/0049-3848(93)90036-n

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání